A Phase I/II Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs ALT 803 (Primary) ; ALT 803 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Altor BioScience Corporation
- 19 Jan 2018 Planned End Date changed from 1 Jan 2020 to 1 Oct 2020.
- 31 Oct 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2017.
- 31 Oct 2017 Status changed from recruiting to active, no longer recruiting.